%0 Journal Article
%T Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review.
%A Zhang Z
%A Zhu L
%A Wang Z
%A Hua N
%A Hu S
%A Chen Y
%J Prog Lipid Res
%V 91
%N 0
%D 2023 07 19
%M 37473965
%F 14.673
%R 10.1016/j.plipres.2023.101240
%X Adipokines play a significant role in cardiometabolic diseases. Asprosin, a newly discovered adipokine, was first identified as a glucose-raising protein hormone. Asprosin also stimulates appetite and regulates glucose and lipid metabolism. Its identified receptors so far include Olfr734 and Ptprd. Clinical studies have found that asprosin may be associated with cardiometabolic diseases. Asprosin may have diagnostic and therapeutic potential in obesity, diabetes, metabolic syndrome and atherosclerotic cardiovascular diseases. Herein, the structure, receptors, and functions of asprosin and its relationship with cardiometabolic diseases are summarized based on recent findings.